Kalkine has a fully transformed New Avatar.
Last update at 2025-07-02T02:05:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Sun 23 Jul 23, 12:44 AMThose who invested in Rhythm Biosciences (ASX:RHY) three years ago are up 914%
Tue 28 Mar 23, 08:11 PMWe're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Sun 12 Feb 23, 11:37 PMCompanies Like Rhythm Biosciences (ASX:RHY) Are In A Position To Invest In Growth
Tue 30 Aug 22, 09:02 PMWhat Percentage Of Rhythm Biosciences Limited (ASX:RHY) Shares Do Insiders Own?
Mon 25 Jul 22, 09:47 PMIs Rhythm Biosciences Limited (ASX:RHY) Popular Amongst Insiders?
Tue 15 Feb 22, 11:06 PMBreakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Income before tax | -8.21756M | -8.79352M | -6.61215M | -4.02298M | -2.54616M |
Minority interest | - | - | - | - | - |
Net income | -8.21756M | -6.31618M | -7.72105M | -4.13078M | -1.37748M |
Selling general administrative | 7.33M | 5.33M | 2.97M | 2.00M | 2.28M |
Selling and marketing expenses | 0.18M | 0.56M | 0.06M | 0.04M | 0.30M |
Gross profit | -0.32673M | -0.17238M | -2.17580M | -1.35153M | -1.47686M |
Reconciled depreciation | 0.19M | 0.10M | 0.15M | 0.14M | 0.07M |
Ebit | -11.54167M | -11.24589M | -6.61175M | -4.01519M | -3.71484M |
Ebitda | -11.35229M | -11.14441M | -6.46510M | -3.87390M | -3.64948M |
Depreciation and amortization | 0.19M | 0.10M | 0.15M | 0.14M | 0.07M |
Non operating income net other | - | - | - | - | - |
Operating income | -11.54167M | -11.24589M | -6.61175M | -4.01519M | -3.71484M |
Other operating expenses | 11.54M | 11.25M | 7.73M | 4.16M | 3.71M |
Interest expense | - | 0.02M | 0.00040M | 0.00780M | 0.00000M |
Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
Interest income | 0.23M | 0.02M | 0.01M | 0.00780M | 0.14M |
Net interest income | 0.23M | 0.02M | 0.01M | 0.04M | 0.14M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | -0.22827M | -2.47734M | 1.11M | 0.11M | -1.16868M |
Total revenue | 0.23M | 0.02M | 0.01M | 0.05M | 0.14M |
Total operating expenses | 11.54M | 11.25M | 7.73M | 4.16M | 3.71M |
Cost of revenue | 0.56M | 0.20M | 2.19M | 1.40M | 1.62M |
Total other income expense net | 3.10M | 2.45M | -0.00040M | -0.00780M | 1.17M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -8.21756M | -8.79352M | -6.61215M | -4.02298M | -2.54616M |
Net income applicable to common shares | -8.21756M | -8.79352M | -6.61215M | -4.02298M | -2.54616M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
Total assets | 1.52M | 7.70M | 8.44M | 3.07M | 2.65M |
Intangible assets | - | 0.39M | 0.43M | 0.46M | 0.50M |
Earning assets | - | - | - | - | - |
Other current assets | 0.09M | 0.12M | 0.09M | 0.06M | 0.02M |
Total liab | 0.65M | 1.82M | 1.07M | 1.36M | 0.80M |
Total stockholder equity | 0.87M | 5.87M | 7.37M | 1.71M | 1.84M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 0.27M | 0.35M | 0.57M | 0.74M | 0.19M |
Common stock | 34.45M | 31.55M | 27.83M | 15.98M | 10.04M |
Capital stock | - | 31.55M | 27.83M | 15.98M | 10.04M |
Retained earnings | -38.67417M | -31.81741M | -23.59986M | -14.80633M | -8.38819M |
Other liab | - | 0.06M | 0.05M | 0.02M | 0.00843M |
Good will | - | - | - | - | - |
Other assets | 0.00000M | - | - | - | - |
Cash | 0.71M | 4.12M | 7.55M | 2.23M | 1.80M |
Cash and equivalents | - | - | - | 2.23M | 1.80M |
Total current liabilities | 0.56M | 1.77M | 0.93M | 1.34M | 0.79M |
Current deferred revenue | - | - | - | - | - |
Net debt | -0.54567M | -4.03958M | -7.38028M | -2.22840M | -1.75552M |
Short term debt | 0.08M | 0.08M | 0.09M | 0.00000M | 0.04M |
Short long term debt | - | - | - | - | - |
Short long term debt total | 0.16M | 0.08M | 0.17M | - | 0.04M |
Other stockholder equity | - | 6.14M | 3.14M | 0.53M | 0.19M |
Property plant equipment | - | 0.10M | 0.24M | 0.11M | 0.14M |
Total current assets | 0.89M | 7.12M | 7.77M | 2.49M | 2.01M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | 5.48M | 6.95M | 1.24M | 1.35M |
Short term investments | 0.04M | 0.04M | 0.04M | 0.04M | 0.04M |
Net receivables | 0.04M | 0.07M | 0.08M | 0.16M | 0.14M |
Long term debt | - | - | - | - | - |
Inventory | - | 2.77M | - | - | - |
Accounts payable | 0.21M | 1.33M | 0.28M | 0.60M | 0.56M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | 5.09M | 6.14M | 3.14M | 0.53M | 0.19M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | 10.04M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 0.35M | - | - | -0.00003M | - |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 0.63M | 0.58M | 0.67M | 0.58M | 0.64M |
Capital lease obligations | - | 0.08M | 0.17M | - | 0.04M |
Long term debt total | - | 0.00000M | 0.08M | 0.00000M | 0.00000M |
Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Investments | -0.09912M | -0.02701M | -0.06827M | -0.04553M | -0.11026M |
Change to liabilities | 0.00000M | -0.55232M | 0.51M | 0.36M | 0.16M |
Total cashflows from investing activities | -0.09912M | -0.02701M | -0.06827M | -0.04553M | -0.11026M |
Net borrowings | -0.08553M | -0.00766M | -0.04244M | -0.14222M | -0.14222M |
Total cash from financing activities | 3.63M | 11.85M | 5.90M | -0.14222M | -0.14222M |
Change to operating activities | -0.07549M | 0.07M | 0.04M | 0.02M | 0.04M |
Net income | -8.21756M | -6.31618M | -6.61215M | -4.02298M | -2.54616M |
Change in cash | -3.42624M | 5.32M | 0.43M | -2.93036M | -3.05186M |
Begin period cash flow | 7.55M | 2.23M | 1.80M | 4.73M | 7.78M |
End period cash flow | 4.12M | 7.55M | 2.23M | 1.80M | 4.73M |
Total cash from operating activities | -6.95761M | -6.21471M | -5.40249M | -2.74260M | -2.94160M |
Issuance of capital stock | 3.74M | 12.32M | 6.17M | - | - |
Depreciation | 0.19M | 0.10M | 0.15M | 0.14M | 0.07M |
Other cashflows from investing activities | - | - | - | - | 0.00000M |
Dividends paid | - | - | - | - | - |
Change to inventory | -2.76668M | -2.76668M | -2.76668M | -2.76668M | - |
Change to account receivables | 0.91M | 0.07M | -0.04020M | 0.66M | -0.76246M |
Sale purchase of stock | -0.02422M | -0.46785M | -0.22512M | - | 0.00000M |
Other cashflows from financing activities | -0.08553M | -0.00766M | -0.04244M | -0.05986M | -0.11026M |
Change to netincome | 3.00M | 2.61M | 0.56M | 0.10M | 0.09M |
Capital expenditures | 0.10M | 0.03M | 0.07M | 0.05M | 0.11M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | 3.32M | 2.45M | 1.18M | 0.84M | 0.43M |
Stock based compensation | - | - | - | - | - |
Other non cash items | - | 6.21M | 6.47M | 3.88M | 2.48M |
Free cash flow | -0.09912M | -6.24171M | -0.06827M | -0.04553M | -0.11026M |
Sector: Healthcare Industry: Diagnostics & Research
Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
---|---|---|---|---|---|---|---|---|
RHY Rhythm Biosciences Ltd |
-0.003 5.56% | 0.05 | - | - | 5.11 | 3.32 | -11.0908 | |
SHL Sonic Healthcare Ltd |
0.18 0.67% | 26.90 | 23.57 | 20.66 | 1.38 | 1.54 | 1.82 | 9.67 |
IDX Integral Diagnostics Ltd |
- -% | 2.53 | 126.00 | 17.15 | 1.91 | 1.29 | 2.85 | 18.94 |
HLS Healius Ltd |
-0.01 1.33% | 0.74 | - | 74.07 | 0.33 | 0.58 | 1.08 | 10.14 |
ACL Australian Clinical Labs Ltd |
-0.05 1.78% | 2.76 | 18.13 | 13.19 | 0.73 | 3.18 | 1.15 | 4.53 |
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.
Bio21 Institute, Parkville, VIC, Australia, 3010
Name | Title | Year Born |
---|---|---|
Mr. Otto Leslie-Steven Buttula AIMM, B.Ec., Grad. Dip., MAICD | Exec. Chairman | 1964 |
Mr. Glenn Gilbert | MD, CEO & Director | NA |
Dr. Trevor John Lockett Ph.D. | Technical Director, Chair of the Clinical Advisory Board & Exec. Director | NA |
Mr. Paul Smith | Chief Financial Officer & Joint Company Sec. | NA |
Ms. Andrea Steele LLB B Com LLM | Gen. Counsel & Company Sec. | NA |
Ms. Elena Deak | Chief Commercial Officer | NA |
Mr. Otto Leslie-Steven Buttula AIMM, B.Ec., Grad. Dip., MAICD | Executive Chairman | 1964 |
Mr. Guy Carisbrooke | Financial Controller | NA |
Ms. Andrea Steele LLB B Com LLM | General Counsel & Joint Company Secretary | NA |
Mr. James Stephen Barrie CPA | Joint Company Secretary | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.